Non-invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small-animal FDG-PET/CT

• Material Type: 博士論文
• Title: Non-invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small-animal FDG-PET/CT
• Author/Editor: Aoyama, Mariko; Takizawa, Hiromitsu; Otani, Tamaki; Inoue, Seiya; Kawakita, Naoya; Tsuboi, Mitsuhiro; Bando, Yoshimi; Uehara, Hisanori; Kondo, Kazuya; Tangoku, Akira
• Author Heading: Aoyama, Mariko; Takizawa, Hiromitsu; Otani, Tamaki; Inoue, Seiya; Kawakita, Naoya; Tsuboi, Mitsuhiro; Bando, Yoshimi; Uehara, Hisanori; Kondo, Kazuya; Tangoku, Akira
• Publication, Distribution, etc.: Spandidos Publications
• Publication Date: 2020-08-07
• Publication Date (W3CDTF): 2020-08-07
• Alternative Title: 甲状腺未分化癌同所移植SCIDマウスモデルへのパクリタキセルとレンバチニブの有効性に対する小動物用FDG-PET/CTを用いた非侵襲的モニタリング; MONITORING ANAPLASTIC THYROID CANCER MODELS BY PET/CT
• Periodical title: Oncology Reports
• No. or year of volume/issue: 44 4
• Volume: 44
• Issue: 4
• Pages: 1709-1716
• ISSN (Periodical Title): ISSN : 1021-335X; ISSN : 1791-2431
• Degree grantor/type: 徳島大学
• Date Granted: 2020-09-24
• Dissertation Number: 甲第3461号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: anaplastic thyroid carcinoma; orthotopic model; 18F-FDG PET/CT; paclitaxel; lenvatinib
• Target Audience: 一般
• Note (General): Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid carcinoma with a poor prognosis. Thus, suitable preclinical tumor models are required for the development of new ATC therapies. In the present study, orthotopic tumor xenograft models were established using ATC cell lines and SCID mice, and tumor invasion and the effects of anticancer drugs were evaluated using positron emission tomography/computed tomography (PET/CT) to repeatedly and non-invasively monitor these models. Three ATC cell lines (8305c, 8505c, and ACT-1) were used. Their sensitivities to two anticancer drugs (paclitaxel and lenvatinib) were investigated. The 8505c cell line was orthotopically implanted into SCID mice, which were then divided into three groups: no chemotherapy, paclitaxel (5 mg/kg, administered intraperitoneally, every week), and lenvatinib (5 mg/kg, oral route, every day) groups. PET/CT was performed and tumor growth and the effects of anticancer drugs based on tumor volume and fludeoxyglucose (FDG) uptake were evaluated. 8505c cells exhibited the highest sensitivity to the anticancer drugs. In mice implanted with 8505c cells, continuous increases in FDG uptake associated with tumor growth were detected on PET/CT in the group that received no chemotherapy. The tumor volume and FDG uptake increased by 91.5- and 2.4-fold, respectively, within 2 weeks. The increase observed in tumor volume was 26.9- and 12.2-fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. Furthermore, the increase in FDG uptake was 1.8-fold and 1.6-fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. In our orthotopic SCID mouse model, tumor growth and the effects of anticancer drugs were repeatedly and non-invasively monitored using PET/CT. The present method is useful for the development of new ATC treatments.
• Format (IMT): application/pdf
• Source: fulltext; http://repo.lib.tokushima-u.ac.jp/files/public/11/115331/20201009141805924875/k3461_abstract_review.pdf; http://repo.lib.tokushima-u.ac.jp/files/public/11/115331/20201009141806421247/k3461_fulltext.pdf
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.3892/or.2020.7720
• Periodical Title (NCID): AA11016405; https://ci.nii.ac.jp/ncid/AA11016405
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 徳島大学 : 徳島大学機関リポジトリ